NuCana (NCNA) Total Current Liabilities (2016 - 2025)
NuCana (NCNA) reported Total Current Liabilities of $6.4 million for Q4 2025, down 42.68% on a YoY basis from $11.1 million in Q4 2024, and down 24.66% sequentially from $8.5 million in Q3 2025.
NuCana (NCNA) Total Current Liabilities (2016 - 2025) Analysis & Trends
NuCana (NCNA) has 10 years of Total Current Liabilities data on file, last reported at $6.4 million in Q4 2025.
- For the quarter ending Q4 2025, Total Current Liabilities fell 42.68% year-over-year to $6.4 million; the trailing twelve-month figure through Dec 2025 stood at $6.4 million (down 42.68% YoY), and the FY2025 full-year result was $6.3 million, down 42.95% from the prior year.
- Total Current Liabilities slipped to $6.4 million in Q4 2025, from $8.5 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $22.6 million in Q4 2022 to a low of $6.4 million in Q4 2025.
- A 5-year average of $15.0 million and a median of $15.8 million in 2021 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities jumped 61.21% in 2021 and slumped 56.65% in 2025, its largest moves.
- Tracing NCNA's Total Current Liabilities over 5 years: stood at $15.8 million in 2021, then jumped by 43.41% to $22.6 million in 2022, then sank by 30.54% to $15.7 million in 2023, then slipped by 29.3% to $11.1 million in 2024, then tumbled by 42.68% to $6.4 million in 2025.
- Business Quant data shows NCNA's Total Current Liabilities at $6.4 million in Q4 2025, $8.5 million in Q3 2025, and $11.6 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 1.35 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.38 Mn |
| Sep 30, 2025 | 8.46 Mn |
| Jun 30, 2025 | 11.60 Mn |
| Mar 31, 2025 | 9.18 Mn |
| Dec 31, 2024 | 11.12 Mn |
| Sep 30, 2024 | 19.52 Mn |
| Jun 30, 2024 | 20.27 Mn |
| Mar 31, 2024 | 18.32 Mn |
| Dec 31, 2023 | 15.73 Mn |
| Sep 30, 2023 | 15.09 Mn |
| Jun 30, 2023 | 16.94 Mn |
| Mar 31, 2023 | 20.18 Mn |
| Dec 31, 2022 | 22.65 Mn |
| Sep 30, 2022 | 18.22 Mn |
| Jun 30, 2022 | 13.14 Mn |
| Mar 31, 2022 | 16.80 Mn |
| Dec 31, 2021 | 15.79 Mn |
| Sep 30, 2021 | 16.68 Mn |
| Jun 30, 2021 | 10.98 Mn |
| Mar 31, 2021 | 12.50 Mn |